Evidence map›Paper›PMID 11489925›Full record

ReviewThe Journal of clinical investigation2001

Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena.

R V Iozzo, J D San Antonio

Abstract readReview
In one paragraph

Review in The Journal of clinical investigation, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers.

0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

152 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. A functional outside-in signaling network of proteoglycans and matrix molecules regulating autophagy.Matrix biology : journal of the International Society for Matrix Biology · 2021
    Article
  19. Review
  20. Observational

92 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

R V IozzoDepartment of Pathology, Anatomy and Cell Biology, Cellular Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA. iozzo@lac.jci.tju.edu
J D San Antonio

Funding

NEOPLASTIC MODULATION OF PROTEOGLYCAN METABOLISMR01CA039481 · NCI · UNIVERSITY OF PENNSYLVANIA · PI IOZZO, RENATO V. · 1985 to 2020
$7.1M
The Biology of Perlecan in Cancer and AngiogenesisR01CA047282 · NCI · THOMAS JEFFERSON UNIVERSITY · PI IOZZO, RENATO V. · 1990 to 2019
$5.7M
MECHANISMS OF ENDOTHELIAL CELL-COLLAGEN INTERACTIONSR01HL053590 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI SANANTONIO, JAMES D · 2003 to 2007
$1.4M
MECHANISMS OF PROTEOGLYCAN/COLLAGEN INTERACTIONSR29HL053590 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI SANANTONIO, JAMES D · 1997 to 2000
$113k
NCI NIH HHS CA-39481NCI NIH HHS CA-47282NCI NIH HHS R01 CA039481NCI NIH HHS R01 CA047282NHLBI NIH HHS HL-53590NHLBI NIH HHS R01 HL053590NHLBI NIH HHS R29 HL053590
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Neovascularization, PhysiologicAnimalsEndothelial Growth FactorsFibroblast Growth FactorsHeparan Sulfate ProteoglycansHumansLymphokinesModels, CardiovascularNeoplasmsNeovascularization, PathologicSignal TransductionVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsEndothelial Growth FactorsFibroblast Growth FactorsHeparan Sulfate ProteoglycansLymphokinesVascular Endothelial Growth Factor AVascular Endothelial Growth Factors

Identifiers

PMID11489925
PMCPMC209371

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.